{"entity":{"id":"nct07217184","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM","aka":[],"tldr":"A phase 1/2 trial of Belantamab mafodotin, Isatuximab in multiple myeloma, run by GlaxoSmithKline, active and no longer recruiting.","summary":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM is a phase 1/2 interventional study registered as NCT07217184 by GlaxoSmithKline, with 30 participants enrolled, started 2021-07-29 and due to reach its primary completion in 2025-04-17. Interventions recorded: Belantamab mafodotin, Isatuximab. Conditions listed: Multiple Myeloma. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT07217184","url":"https://clinicaltrials.gov/study/NCT07217184"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma","myeloma-relapsed-refractory"],"sections":[],"technologies":["adc","monoclonal-antibody"],"targets":[],"drugs":["belantamab-mafodotin","isatuximab"],"companies":["gsk"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07217184","phase":"1/2","setting":"A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5- Sub-study 5 - Belantamab Mafodotin and Isatuximab in Combination","sponsor":"GlaxoSmithKline","started":"2021-07-29","startedType":"actual","yearReported":2026,"enrolled":30,"enrolledBasis":"registry","outcomes":[{"endpoint":"Dose Expansion (DE) Phase: Number of Participants With Dose Limiting Toxicities (DLT)","primary":true,"unit":"participants","arms":[{"name":"1.9 Milligram (mg)/Kilogram (kg) Belantamab Mafodotin (Q4W) + Isatuximab","n":7,"value":2,"note":"Figures from the ClinicalTrials.gov results section (first posted 2026-06-25), not from a publication"},{"name":"1.4 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab","n":8,"value":0},{"name":"1.9 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab","n":8,"value":1}],"source":"https://clinicaltrials.gov/study/NCT07217184?tab=results"},{"endpoint":"DE Phase: Overall Response Rate (ORR)","unit":"%","arms":[{"name":"1.9 Milligram (mg)/Kilogram (kg) Belantamab Mafodotin (Q4W) + Isatuximab","n":10,"value":20,"note":"95% CI 2.5 to 55.6; Figures from the ClinicalTrials.gov results section (first posted 2026-06-25), not from a publication"},{"name":"1.4 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab","n":10,"value":30,"note":"95% CI 6.7 to 65.2"},{"name":"1.9 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab","n":10,"value":30,"note":"95% CI 6.7 to 65.2"}],"source":"https://clinicaltrials.gov/study/NCT07217184?tab=results"}]},"route":"/trials/nct07217184/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"belantamab-mafodotin","kind":"drug","name":"Belantamab mafodotin","route":"/drugs/belantamab-mafodotin/"},{"id":"isatuximab","kind":"drug","name":"Isatuximab","route":"/drugs/isatuximab/"}],"company":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"}]}}